UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

________________________________________________________________________________________________

FORM 8-K

________________________________________________________________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): ~~April~~June 292, 2026

________________________________________________________________________________________________

Crescent Biopharma, Inc.

(Exact Name of Registrant as Specified in Charter)

________________________________________________________________________________________________


Cayman Islands	001-36177	06-1686563
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

300 Fifth Avenue Waltham, MA		02451
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (617) 430-5595

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

________________________________________________________________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ~~(see General Instruction A.2. below)~~:


o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading symbol(s)

Name of each exchange on which registered

Ordinary Shares, $0.001 par value per share

CBIO

The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 25.~~02 Results~~07 Submission of ~~Operations~~Matters ~~and~~to ~~Financial~~a ~~Condition~~Vote of Security Holders.

On ~~April~~June 292, 2026, Crescent Biopharma, Inc. (the “Company”) ~~issued~~held aits ~~press~~annual ~~release~~general ~~announcing~~meeting of shareholders (the ~~Company’s~~“Annual ~~financial~~Meeting”). ~~results~~At the close of business on April 7, 2026, the record date for the ~~quarter~~Annual ~~ended~~Meeting ~~March~~(the 31“Record Date”), ~~2026~~27,571,935 ordinary shares, par value $0.001 per share (“Ordinary Shares”), were issued and outstanding, and 2,890 Series A ~~copy~~non-voting convertible preferred shares, par value $0.001 per share (“Series A Preferred Shares”), were issued and outstanding. Each Ordinary Share was entitled to one vote per share for the election of Susan Moran, M.D., MSCE and one vote on each of proposals 3, 4 and 5. The holders of each Series A Preferred Share were entitled to 1,000 votes per share, voting as a separate class for the ~~press~~election ~~release~~of isJonathan ~~furnished~~Violin, Ph.D. and voting together with the holders of Ordinary Shares as ~~Exhibit~~a 99single class for the election of Susan Moran, M.1D., toMSCE, ~~this~~and ~~Current~~were ~~Report~~not entitled to vote on ~~Form~~any ~~8-K~~other proposal. The following are the voting results for the proposals considered and isvoted ~~incorporated~~upon ~~herein~~at bythe ~~reference~~Annual Meeting, each of which was described in the Company’s definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on April 21, 2026.

~~The~~Proposal ~~information in this Item 2~~No.02 1A and ~~Exhibits~~Proposal 99No.1 ~~attached~~1B ~~hereto~~- isElection ~~being furnished and shall not be deemed “filed” for purposes~~ of ~~Section~~two 18Class ofII ~~the~~directors ~~Securities~~to ~~Exchange~~serve ~~Act~~until ~~of 1934, as amended (~~the ~~“Exchange~~Company’s ~~Act”),~~2029 orAnnual ~~otherwise~~General ~~subject~~Meeting ~~to the liabilities~~ of ~~that~~Shareholders ~~section,~~and ~~nor~~until ~~shall~~their itrespective besuccessors ~~deemed~~have ~~incorporated~~been byduly ~~reference~~elected ~~into~~and ~~any~~qualified ~~filing~~or byuntil ~~the~~their ~~Company~~earlier ~~under the Securities Act of 1933~~death, ~~as amended~~resignation, disqualification or ~~the Exchange Act, except as expressly set forth by specific reference in such filling~~removal.

Item 9.01 Financial Statements and Exhibits.


	Votes FOR	Votes WITHHELD	Broker Non-Votes
Jonathan Violin, Ph.D. (Proposal No. 1A)	2,890,000	0	0
Susan Moran, M.D., MSCE (Proposal No. 1B)	21,401,136	136,056	2,403,515

~~(d)Exhibits~~Proposal No. 2 - Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

Exhibit No.	Description
Votes FOR	Votes AGAINST	Votes ABSTAINED	Broker Non-Votes
99.1	Press Release issued by Crescent Biopharma, Inc. on April 29, 2026
21,049,101	1,452	154	0
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

Proposal No. 3 - Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers.


Votes FOR	Votes AGAINST	Votes ABSTAINED	Broker Non-Votes
18,346,099	300,217	876	2,403,515

Proposal No. 4 - Approval, on a non-binding advisory basis, of the frequency of future advisory votes to approve the compensation of the Company’s named executive officers.


1 YEAR	2 YEARS	3 YEARS	Votes ABSTAINED	Broker Non-Votes
18,644,881	903	887	521	2,403,515

Based on the foregoing votes, each of Jonathan Violin, Ph.D. and Susan Moran, M.D., MSCE was elected as a Class II director, Proposal 2 and Proposal 3 were approved, and shareholders recommended a one year frequency for future advisory votes to approve named executive officer compensation.

Based on the foregoing voting results and consistent with the recommendation of the Board of Directors of the Company (the “Board”), the Board has determined to hold an advisory vote on the compensation of the Company’s named executive officers every year until the next advisory vote regarding the frequency of future advisory votes on the compensation of the Company’s named executive officers is submitted to the shareholders or the Board otherwise determines that a different frequency for such advisory votes is in the best interest of the Company and its shareholders.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CRESCENT BIOPHARMA, INC.

Date: April 29, 2026

By:

/s/ Joshua Brumm

Date: June 3, 2026

By:

/s/ Joshua Brumm

Name:

Joshua Brumm

Title:

Chief Executive Officer

Filing Compare · CRESCENT BIOPHARMA, INC.